The White House’s decision to safeguard $400m in President’s Emergency Plan for AIDS Relief (PEPFAR) funding to support the global human immunodeficiency virus (HIV) emergency provides “hope” to ...

With the aim of being the largest life science sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

Navamedic has completed its previously announced acquisition of dne pharma's business for up to Nkr225m ($22m).

As supply chain disruption persists in pharma, global logistics providers with the expertise to overcome any challenge are essential.

Acumen has entered a partnership, option and licence agreement with JCR for developing an oligomer-targeted EBD for Alzheimer’s disease.